Clinical Course, Therapeutic Management and Outcome of Coronavirus Disease in Patients With Inborn Errors of Immunity : A Retrospective Multicenter Experience From Iran
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved..
BACKGROUND: Inborn errors of immunity (IEIs) are characterized by defects in the structure and function of the immune system. This study was designed to assess the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on this potentially particularly susceptible group of patients.
METHODS: This retrospective cross-sectional study analyzed patients from 3 referral immunodeficiency centers in Iran. The demographic, clinical, laboratory and therapeutical data of confirmed IEI patients with SARS-CoV-2 infection were collected and analyzed.
RESULTS: A total of 19 IEI patients, 52.6% male and 47.4% female, with coronavirus disease 2019 (COVID-19) were enrolled. The most common diagnosed IEIs were (severe) combined immunodeficiency ((S)CID) (9, 47.4%) and predominantly antibody deficiencies (7, 36.8%). The main presenting symptoms included fever (16, 84.2%), cough (12, 63.2%), dyspnea (9, 47.4%) and myalgia (8, 42.1%). Among additional preexisting comorbidities, atopy ( P = 0.087) and renal disorders ( P = 0.087) were more strongly associated with the development of respiratory failure, although not statistically significant. SARS-CoV-2 infection was determined by polymerase chain reaction (n = 19, 100%) within a median (interquartile range) of 1 (0-6) days following admission. Among all laboratory indices, thrombocytopenia ( P = 0.009) was associated with a need for intensive care unit admission. The overall mortality rate was 36.9% and highest among (S)CID patients (4, 44.4%).
CONCLUSIONS: Severe COVID-19 most frequently affected (S)CID and predominantly antibody deficiencies patients among this multicenter Iranian cohort. Further studies are required to evaluate the impact of additional preexisting comorbidities and the development of thrombocytopenia on the severity and prognosis of COVID-19 in IEIs.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
The Pediatric infectious disease journal - 42(2023), 12 vom: 01. Dez., Seite 1102-1106 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 27.11.2023 Date Revised 27.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1097/INF.0000000000004110 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362479607 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362479607 | ||
| 003 | DE-627 | ||
| 005 | 20231226091329.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/INF.0000000000004110 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1208.xml |
| 035 | |a (DE-627)NLM362479607 | ||
| 035 | |a (NLM)37751625 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karimi, Abdollah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Course, Therapeutic Management and Outcome of Coronavirus Disease in Patients With Inborn Errors of Immunity |b A Retrospective Multicenter Experience From Iran |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.11.2023 | ||
| 500 | |a Date Revised 27.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved. | ||
| 520 | |a BACKGROUND: Inborn errors of immunity (IEIs) are characterized by defects in the structure and function of the immune system. This study was designed to assess the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on this potentially particularly susceptible group of patients | ||
| 520 | |a METHODS: This retrospective cross-sectional study analyzed patients from 3 referral immunodeficiency centers in Iran. The demographic, clinical, laboratory and therapeutical data of confirmed IEI patients with SARS-CoV-2 infection were collected and analyzed | ||
| 520 | |a RESULTS: A total of 19 IEI patients, 52.6% male and 47.4% female, with coronavirus disease 2019 (COVID-19) were enrolled. The most common diagnosed IEIs were (severe) combined immunodeficiency ((S)CID) (9, 47.4%) and predominantly antibody deficiencies (7, 36.8%). The main presenting symptoms included fever (16, 84.2%), cough (12, 63.2%), dyspnea (9, 47.4%) and myalgia (8, 42.1%). Among additional preexisting comorbidities, atopy ( P = 0.087) and renal disorders ( P = 0.087) were more strongly associated with the development of respiratory failure, although not statistically significant. SARS-CoV-2 infection was determined by polymerase chain reaction (n = 19, 100%) within a median (interquartile range) of 1 (0-6) days following admission. Among all laboratory indices, thrombocytopenia ( P = 0.009) was associated with a need for intensive care unit admission. The overall mortality rate was 36.9% and highest among (S)CID patients (4, 44.4%) | ||
| 520 | |a CONCLUSIONS: Severe COVID-19 most frequently affected (S)CID and predominantly antibody deficiencies patients among this multicenter Iranian cohort. Further studies are required to evaluate the impact of additional preexisting comorbidities and the development of thrombocytopenia on the severity and prognosis of COVID-19 in IEIs | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Jamee, Mahnaz |e verfasserin |4 aut | |
| 700 | 1 | |a Shokri, Youssef |e verfasserin |4 aut | |
| 700 | 1 | |a Heidari, Atefeh |e verfasserin |4 aut | |
| 700 | 1 | |a Nazarpack, Fatemeh |e verfasserin |4 aut | |
| 700 | 1 | |a Fallahi, Mazdak |e verfasserin |4 aut | |
| 700 | 1 | |a Shiari, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Philip H |e verfasserin |4 aut | |
| 700 | 1 | |a Sharifinejad, Niusha |e verfasserin |4 aut | |
| 700 | 1 | |a Sharafian, Samin |e verfasserin |4 aut | |
| 700 | 1 | |a Mahdaviani, Seyed Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Mansouri, Davood |e verfasserin |4 aut | |
| 700 | 1 | |a Zeinali, Amirreza |e verfasserin |4 aut | |
| 700 | 1 | |a Alyasin, Soheila |e verfasserin |4 aut | |
| 700 | 1 | |a Chavoshzadeh, Zahra |e verfasserin |4 aut | |
| 700 | 0 | |a Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Mesdaghi, Mehrnaz |e investigator |4 oth | |
| 700 | 1 | |a Khalili, Mitra |e investigator |4 oth | |
| 700 | 1 | |a Armin, Shahnaz |e investigator |4 oth | |
| 700 | 1 | |a Ghanaie, Roxana Mansour |e investigator |4 oth | |
| 700 | 1 | |a Tabatabaei, Sedigheh Rafiei |e investigator |4 oth | |
| 700 | 1 | |a Fahimzad, Seyed Alireza |e investigator |4 oth | |
| 700 | 1 | |a Eslami, Narges |e investigator |4 oth | |
| 700 | 1 | |a Nabavizadeh, Seyed Hesamedin |e investigator |4 oth | |
| 700 | 1 | |a Esmaeilzadeh, Hossein |e investigator |4 oth | |
| 700 | 1 | |a Kanannejad, Zahra |e investigator |4 oth | |
| 700 | 1 | |a Babaei, Maryam |e investigator |4 oth | |
| 700 | 1 | |a Mansouri, Mahboubeh |e investigator |4 oth | |
| 700 | 1 | |a Babaei, Delara |e investigator |4 oth | |
| 700 | 1 | |a Fallah, Shahrzad |e investigator |4 oth | |
| 700 | 1 | |a Fard, Nasrin Khakbazan |e investigator |4 oth | |
| 700 | 1 | |a Hashemimoghaddam, Seyedeh Atefeh |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Pediatric infectious disease journal |d 1991 |g 42(2023), 12 vom: 01. Dez., Seite 1102-1106 |w (DE-627)NLM012615706 |x 1532-0987 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:1102-1106 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/INF.0000000000004110 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 12 |b 01 |c 12 |h 1102-1106 | ||